
The deal would create one of the world’s largest satellite broadband providers and could harm market competition. Back in November 2021, US satellite operator ViaSat struck a deal to acquire the UK’s Inmarsat for $7.3 billion.
Now, the UK’s Competition and Markets Authority (CMA) has announced that it is beginning its own review into the acquisition, seeking to ascertain if the deal represents “a substantial lessening of competition within any market or markets in the [UK]”.
The companies said that the tie-up would “create a leading global communications innovator with enhanced scale and scope to affordably, securely and reliably connect the world”, suggesting their complementary assets that would be used to create a “high-capacity hybrid space and terrestrial network”.
In total, the combined company would operate a fleet of 19 satellites in various orbits and using various spectrum bands, with ten more under construction.
At the time, the two operators said that they hoped the deal would close in mid-2022, but it seems that this target was overly ambitious, with various regulatory bodies being asked to weigh in on the matter due to competition concerns.
Last month, the European Commission announced that they had been asked to investigate the deal at the behest of 13 countries, meaning ViaSat will have to wait for clearance before implementing the transaction.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas